Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Guest Editor: S. J. Mather
Smith-Jones P. M.
Nuclear Medicine Service, Department of Radiology Memorial Sloan Kettering Cancer Center New York, NY, USA
In recent years, advances in the rational design of radiopharmaceuticals have helped in the introduction of clinically useful therapeutic agents into the clinic. In particular radiolabeled monoclonal antibodies such as 90Y-ibritumomab and 131I-tositumomab have shown to be clinically successful. More recently, 177Lu has emerged as an attractive radionuclide for use in systemic radiotherapy. Like 131I, it has a longer half-live than 90Y which is more suitable to the pharmacokinetics of monoclonal antibodies, but its chemistry is similar to 90Y and, when internalized, it is retained by the tumor whereas 131I can be quickly released. Metastatic prostate cancer is an attractive target for radioimmunotherapy since the cornerstone of current therapy is hormonal therapy, which is only palliative. Prostate cancer is also known to metastasize to areas such as the lymph nodes and bone marrow, sites that are readily accessible to circulating monoclonal antibodies. This review will look at recent advances to the treatment of metastatic prostate cancer with radiolabeled antibodies with a specific emphasis on 177Lu-huJ591, a labeled monoclonal antibody currently under clinical evaluation.